checkAd
    Startseite > Aktien > IO Biotech > Nachrichten
    IO Biotech Aktie
    1,3800
     
    USD
    -1,43 %
    -0,0200 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,3600
     
    USD
    200 STK
    Geldkurs 17.05.24
    1,3900
     
    USD
    1.200 STK
    Briefkurs 17.05.24
    ISIN: US4497781090 · WKN: A3C6ZG · SYM: IOBT · USA

    Neueste Nachrichten

    IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
    14.05.24 · globenewswire · IO Biotech
    IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · IO Biotech
    IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
    15.04.24 · globenewswire · IO Biotech
    IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
    09.04.24 · globenewswire · IO Biotech
    IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
    05.04.24 · globenewswire · IO Biotech
    IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
    06.03.24 · globenewswire · IO Biotech
    IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
    05.03.24 · globenewswire · IO Biotech
    IO Biotech to Present at 44th Annual Cowen Health Care Conference
    26.02.24 · globenewswire · IO Biotech
    IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
    21.12.23 · globenewswire · IO Biotech
    IO Biotech Announces 2023 Third Quarter Results
    13.11.23 · globenewswire · IO Biotech
    IO Biotech Appoints Helen Collins, MD, to its Board of Directors
    13.11.23 · globenewswire · IO Biotech
    IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
    10.11.23 · globenewswire · IO Biotech